Drug Trial Radar · NCT07122648
Phase 2 Trial to Evaluate the Efficacy, Safety of Allogeneic Mitochondria (PN-101) in Patients With Refractory Polymyositis or Dermatomyositis
Last checked: Nov 19, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Dec 2025
Primary completion
Apr 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- Paean Biotechnology Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The efficacy of PN-101 in subjects with polymyositis or dermatomyositis will be evaluated at Week 12 using IMACS-TIS in comparison with the placebo control group. The safety and efficacy will be evaluated following administration of PN-101 to subjects with polymyositis or dermatomyositis, in comparison with the placebo group
Conditions
- Polymyositis
- Dermatomyositis
Interventions
placeboBiological
Participants will receive a single IV dose of 300 µg of placebo
PN-101Biological
Participants will receive a single IV dose of 300 µg of PN-101
PN-101Biological
Participants will receive a single IV dose of 600 µg of PN-101.
Primary outcomes
What the sponsor says the trial is designed to measure.
- International Myositis And Clinical Studies group-Total Improvement Score (IMACS-TIS)Time frame: 12 weeks after the IP administration
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Kyung Hee University Medical Center
Seoul, South Korea
Seoul National University
Seoul, South Korea
Soon Chun Hyang University Hospital Seoul
Seoul, South Korea
Chung-Ang University Hospital
Seoul, South Korea
Chung-Ang University Gwang Myeong Hospital
Gwangmyeong, Gyeonggi-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.